Mithra Pharmaceuticals « Terug naar discussie overzicht

Mithra in 2020 - Geduld is een schone zaak

962 Posts, Pagina: « 1 2 3 4 5 6 7 ... 45 46 47 48 49 » | Laatste
wfranken
0
Statement from the CEO and the Board of Directors of Mithra
following the articles published in the Belgian press
Liege, Belgium, 23 January 2020 – Following publications in the press on Wednesday, 22 January 2020
regarding an alleged insider trading offence attributed to Mr. François Fornieri, CEO of Mithra
Pharmaceuticals, Mr. Fornieri vigorously contests any involvement in any such offence and deeply
regrets the prejudice caused by this alleged information to Mithra (Euronext Brussels: MITRA), a
company dedicated to Women’s Health.
"I vehemently deny that I would have committed an offence and would have given any inside
information to anyone outside of Mithra. I deeply regret the impact that these media releases have
had on Mithra, a rapidly developing listed company, and that violate the confidentiality of the
investigation. I am available to answer any questions in all transparency that the competent authorities
may have. Let them do their investigative work without any further disruption", says François Fornieri.
The Board of Directors of Mithra, chaired by Marc Coucke, also reacted "by reiterating its full
confidence in its CEO and expressly asking him to continue his mission as CEO and to carry out the
group's strategy as always. The members of our Board of Directors reaffirm their full commitment to
Mithra, one of Belgium's leading biotech companies, and their firm determination to scrupulously
follow good governance practices"
FatCool
0
In tegenstelling tot andere anti-conceptie hormonen die verdacht worden van het vergroten van de kans op borstkanker lijkt het natuurlijke hormoon Estetrol schoon te zijn.

In december 2019 publiceerde Pantarhei de resultaten van een fase 1 studie in oncologie:

www.pantarheibio.com/news/

Estetrol has DUAL efficacy in the treatment of end-stage breast cancer

The pregnancy estrogen Estetrol (E4) has a DUAL effect when treating heavily-pre-treated women with advanced breast cancer who have no further treatment options. First, E4 has an anti-tumor effect and second, E4 improves wellbeing.

The Dutch biotech company Pantarhei Oncology presents on December 13, 2019 at the San Antonio Breast Cancer Symposium (SABCS) in the USA the results of the first clinical study with High Doses of the fetal estrogen Estetrol (HDE4) in women with advanced end-stage breast cancer.

Nine women without further treatment options participated in the study and were treated with 20, 40 or 60 mg E4 per day for 12 weeks. Anti-tumor effects after 12 weeks treatment were confirmed in 5 of 9 women and strong improvement of wellbeing occurred in 7 of 9 patients.

Uit het persbericht nog nadere informatie:

IMPROVEMENT OF QUALITY OF LIFE
Women with advanced, estrogen sensitive breast cancer (75% of all breastcancer patients) are generally treated first with anti-estrogen drugs such as tamoxifen, aromatase inhibitors and fulvestrant and more recently also with CDK4/6 inhibitors and everolimus. These treatments are effective for some time, but recurrence of tumor growth occurs in almost all cases, leaving only chemotherapy as the final treatment option. However, at that stage, the tumors may have become sensitive to High Dose Estrogen (HDE) treatment. In addition, due to previous anti-estrogen treatment, most ofthese patients have developed serious estrogen deficiency complaints such as extreme fatigue, frequent hot flushes, sleep disturbances, mood changes and depression, sexual problems, cognition and concentration disturbances and they may also loose bone mass and have an increased risk of fractures. These signs and symptoms of estrogen deficiency are influenced favorably by HDE4 treatment, with significant improvement of quality of life.

THE DUAL EFFICACY OFESTETROL
The principle investigator of the study at the University Hospital in Mainz, Germany, Prof Marcus Schmidt, says: “We were confident about the safety of Estetrol, but its dual efficacy, the anti-tumor effect and the positive effect on wellbeing, surprised us. This ‘feeling better phenomenon’ was described by one of my patients as ‘feeling less down and exhausted; instead feeling much more optimistic, powerful and positive on Estetrol’”. This patient had serious depression during earlier anti-estrogenic treatments. After completion of the 12-week study, she asked for continuation of E4 treatment and she has now been using HDE4 for almost two years.

Further larger studies are needed to confirm these findings, which requires an investment of €20 million. Pantarhei is looking for a pharmaceuticalpartner or other investors to continue the development of Estetrol and make this new DUAL efficacy treatment available for patients with end-stage advanced breast cancer as soon as possible.
FatCool
0
Fornieri is druk met van alles en nog wat, waar hij blijkbaar niet veel haast mee heeft is het indienen van de Estelle dossiers bij EMA en FDA. Belooft voor het eind van 2019 is het indienen blijkbaar vertraagd.

Je zou toch zeggen dat na de publicatie van de Europese resultaten in november 2018 en de USA resultaten in januari 2019 de data nu toch wel een keer grondig geanalyseerd zou zijn.

fc
dany 1964
0
joe123
0
Wat is er gaande .Min 6 procent naar beneden gebeurd niet zomaar.Het is nog nooit zo stil geweest bij Mithra omtrent estelle en donesta.Het is ooit anders geweest toen Fornieri hoog van de toren blies waarbij hij blufte dat Mithra zo groot dan Bayer kon worden.Hoop doet leven zeker.
mentie
0
Niemand heeft blijkbaar een verklaring waarom er vandaag meer dan 6% afgaat. Zelfs in ´de tijd` wordt er geen letter van Mithra gesproken. Als Fornieri en Coucke lef hebben kopen ze nu aandelen bij ofwel wordt de koers hier zodanig gedrukt dat het kan bedrijf voor een centje kan overgenomen worden?
FilipVanderAa
0
Koersdoelverlaging van Kempen, van 32 naar 25 Euro, advies blijft neutral. In deze tijden van virussen heeft een aandeel niet veel nodig om uit de gratie te vallen bij beleggers. Als de pillen echt doen wat mithra beweert, dan hoeven we ons geen zorgen te maken om dit hobbelig parcours. Buckle up, it's going to be a bumpy ride.
FatCool
1
Gewoon een gebrek aan kopers en een paar iets grotere verkopers drukken het aandeel in de min. Ik zou er vooral niets achter zoeken. Koopwaardig onder de €20.

Filing van Estelle is een (eerste) bericht dat nodig is...

fc
de tuinman
1
quote:

XiXiX schreef op 4 februari 2020 15:50:


Stoploss uitgetikt ?


Ik zet die nooit bij biotech aandelen.
mentie
0
Als er niets aan de hand is kan het management ook niets communiceren . Zonde om op zo`n mooie beursdag nog dieper te zakken.
FilipVanderAa
0
nnieuws.be/artikel/ook-farmabedrijf-m...
Nog een bedrijf dat zich gaat toeleggen op vrouwengezondheid. Misschien zijn ze wel geïnteresseerd in een overname. Diepe zakken, je weet maar nooit
mentie
0
Zou een ideale timing zijn, want het Mithra aandeel staat momenteel spotgoedkoop....
MisterBlues
0
quote:

FatCool schreef op 28 januari 2020 23:49:


In tegenstelling tot andere anti-conceptie hormonen die verdacht worden van het vergroten van de kans op borstkanker lijkt het natuurlijke hormoon Estetrol schoon te zijn.

In december 2019 publiceerde Pantarhei de resultaten van een fase 1 studie in oncologie:

www.pantarheibio.com/news/

Estetrol has DUAL efficacy in the treatment of end-stage breast cancer

The pregnancy estrogen Estetrol (E4) has a DUAL effect when treating heavily-pre-treated women with advanced breast cancer who have no further treatment options. First, E4 has an anti-tumor effect and second, E4 improves wellbeing.

The Dutch biotech company Pantarhei Oncology presents on December 13, 2019 at the San Antonio Breast Cancer Symposium (SABCS) in the USA the results of the first clinical study with High Doses of the fetal estrogen Estetrol (HDE4) in women with advanced end-stage breast cancer.

Nine women without further treatment options participated in the study and were treated with 20, 40 or 60 mg E4 per day for 12 weeks. Anti-tumor effects after 12 weeks treatment were confirmed in 5 of 9 women and strong improvement of wellbeing occurred in 7 of 9 patients.

Uit het persbericht nog nadere informatie:

IMPROVEMENT OF QUALITY OF LIFE
Women with advanced, estrogen sensitive breast cancer (75% of all breastcancer patients) are generally treated first with anti-estrogen drugs such as tamoxifen, aromatase inhibitors and fulvestrant and more recently also with CDK4/6 inhibitors and everolimus. These treatments are effective for some time, but recurrence of tumor growth occurs in almost all cases, leaving only chemotherapy as the final treatment option. However, at that stage, the tumors may have become sensitive to High Dose Estrogen (HDE) treatment. In addition, due to previous anti-estrogen treatment, most ofthese patients have developed serious estrogen deficiency complaints such as extreme fatigue, frequent hot flushes, sleep disturbances, mood changes and depression, sexual problems, cognition and concentration disturbances and they may also loose bone mass and have an increased risk of fractures. These signs and symptoms of estrogen deficiency are influenced favorably by HDE4 treatment, with significant improvement of quality of life.

THE DUAL EFFICACY OFESTETROL
The principle investigator of the study at the University Hospital in Mainz, Germany, Prof Marcus Schmidt, says: “We were confident about the safety of Estetrol, but its dual efficacy, the anti-tumor effect and the positive effect on wellbeing, surprised us. This ‘feeling better phenomenon’ was described by one of my patients as ‘feeling less down and exhausted; instead feeling much more optimistic, powerful and positive on Estetrol’”. This patient had serious depression during earlier anti-estrogenic treatments. After completion of the 12-week study, she asked for continuation of E4 treatment and she has now been using HDE4 for almost two years.

Further larger studies are needed to confirm these findings, which requires an investment of €20 million. Pantarhei is looking for a pharmaceuticalpartner or other investors to continue the development of Estetrol and make this new DUAL efficacy treatment available for patients with end-stage advanced breast cancer as soon as possible.


Bedankt voor je post!

Je voorzichtige formulering spreekt boekdelen: “In tegenstelling tot andere anti-conceptie hormonen die verdacht worden van het vergroten van de kans op borstkanker lijkt het natuurlijke hormoon Estetrol schoon te zijn.”

Het kan wel zo zijn maar dat wil niet zeggen dat de publieke voorzichtigheid of zelfs paranoia hierdoor zijn weggenomen. Vrouwen/eindgebruikers kunnen het zekere voor het onzekere gaan nemen door de producten Estelle en Donesta van Mithra links te laten liggen gezien de andere feiten en/of geruchten rondom hormoontherapie.

Ik ga Mithra benaderen hoe ze hier mee omgaan als het aankomt op de verkoop.


Iceman
0
Vers koopadvies voor Mithra
Mooi nieuws voor Mithra MITRA0,00% deze ochtend. Berenberg start de opvolging van de Belgische specialist in vrouwengeneeskunde met een koopadvies en een koersdoel van 40 euro.

bron: de tijd
962 Posts, Pagina: « 1 2 3 4 5 6 7 ... 45 46 47 48 49 » | Laatste
Aantal posts per pagina:  20 50 100 | Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met uw e-mailadres en wachtwoord.

Direct naar Forum

Detail

Vertraagd 24 sep 2021 17:35
Koers 17,800
Verschil -0,700 (-3,78%)
Hoog 18,440
Laag 17,760
Volume 144.122
Volume gemiddeld 47.217
Volume gisteren 149.718

Brussel real time stocks quotedata by Euronext. Other real time EU stocks, by Cboe Europe Ltd.; US stocks by NYSE & Cboe BZX Exchange, 15 min. delayed
#/^ Index indications calculated real time, zie disclaimer, streaming powered by: Infront